Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | C5 | P01031 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848970 | 0.73 | L3MBTL1 (0.39) | L3MBTL1SMN1; SMN2LMNAHTTPTGS1 | |
| SCHEMBL18891664 | 0.67 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1GAAMAPK1 | |
| SCHEMBL1044787 | 0.66 | NOTUM (0.41) | L3MBTL1ALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL18900601 | 0.65 | GAA (0.38) | PTGS2L3MBTL1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15570057 | 0.64 | FABP3 (0.39) | ALDH1A1HSD17B10SMN1; SMN2LMNAHTT | |
| SCHEMBL19622541 | 0.64 | KMT2A (0.38) | L3MBTL1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL7629389 | 0.64 | GRM1 (0.42) | PTGS2ALDH1A1TDP1AKR1C3AKR1C2 | |
| SCHEMBL7146446 | 0.64 | PTGS2 (0.41) | PTGS2ALDH1A1TDP1AKR1C3AKR1C2 | |
| SCHEMBL6399236 | 0.64 | PTGS2 (0.41) | PTGS2ALDH1A1TDP1AKR1C3AKR1C2 | |
| SCHEMBL7152622 | 0.64 | PTGS2 (0.41) | PTGS2ALDH1A1TDP1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223783-B2 | For example, 3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-N-methyl-N-(2-methylaminoethyl)-propionamide; tyrosine kinase inhibitors used to treat various kinds of cancer | THERAVANCE, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060142281-A1 | Indolinone derivatives | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-06-29 | — | — | US | disclosed |
| US-7060703-B2 | Indolinone derivatives | THERAVANCE, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1458713-B1 | INDOLINONE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | THERAVANCE INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040198804-A1 | i.e., 3-[3,5-dimethyl-4-[3-oxo-3-(piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one, in which the piperazine may be 4-substituted with methyl or ethyl and salts are tyrosine kinase inhibitors used to treat various kinds of cancer | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-10-07 | — | — | US | disclosed |
| EP-1458713-A1 | INDOLINONE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Theravance, Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6686362-B2 | TYROSINE KINASE INHIBITORS | THERAVANCE, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030171378-A1 | Indolinone derivatives | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2003057690-A1 | INDOLINONE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | THERAVANCE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171378-A1 | Indolinone derivatives | ERBB2, IGF1R, ERBB4 | PTGS2 2129/4885L3MBTL1 2427/4885ALDH1A1 452/4885 |
| US-20060142281-A1 | Indolinone derivatives | IGF1R, ERBB2, CDK2 | PTGS2 2608/4885L3MBTL1 1862/4885ALDH1A1 862/4885 |
| US-20040198804-A1 | i.e., 3-[3,5-dimethyl-4-[3-oxo-3-(piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one, in which the piperazine may be 4-substituted with methyl or ethyl and salts are tyrosine kinase inhibitors used to treat various kinds of cancer | ERBB2, RET, ERBB4 | PTGS2 1073/4885L3MBTL1 1842/4885ALDH1A1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.